Jun. 29 at 11:16 AM
Citizens reitd
$VRDN Mkt OP,
$35 and said: Lumvoa (veli) approved by FDA with the expected differentiated label; we reiterate our Market Outperform rating and
$35 risk-adjusted, DCF-derived price target on Viridian Therapeutics.
$AMGN $ALMS IMVT - ROIV RHHBY TRML
Citizens added—On Friday, the FDA approved Lumvoa (veligrotug) for the treatment of thyroid eye disease ahead of its June 30, 2026 PDUFA date.
As expected, the label is inclusive of positive Phase 3 results for both active and chronic TED populations.
The company anticipates immediate launch of Lumvoa and created ViridianCares, a patient support program, to enable broad access of Lumvoa.
We continue to believe that the company is well-prepared to execute the launch of Lumvoa.
